Effects of antisense oligodeoxynucleotides on peptide release from hypothalamoneurohypophysial explants

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 272, Issue 5 41-5, 1997, Pages

  Ludwig, Mike ^a   Morris, Mariana ^b   Sladek, Celia D ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c The Chicago Medical College   (United States)

Author keywords

Osmotic stimulation; Peptides; Posterior pituitary; Potassium; Sodium chloride; Supraoptic nucleus

Indexed keywords

COMPLEMENTARY DNA;

ANIMAL TISSUE; ARTICLE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; NONHUMAN; OSMOSIS; OXYTOCIN RELEASE; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SUPRAOPTIC NUCLEUS; VASOPRESSIN RELEASE;

EID: 0030992942     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.1997.272.5.r1441     Document Type: Article

References (17)

1. Flanagan, L. M., M. M. McCarthy, P. J. Brooks, D. W. Pfaff, and B. S. McEwen. Arginine vasopressin levels after daily infusions of antisense oligonucleotides into the supraoptic nucleus. Ann. NY Acad. Sci. 689: 520-521, 1993.
2. Gura, T. Antisense has growing pains. Science 270: 575-577, 1995.
3. Gyurko, R., D. Wielbo, and M. I. Phillips. Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49: 167-174, 1993.
4. Jirikowski, G. F., P. P. Sanna, D. Maciejewski-Lenoir, and F. E. Bloom. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255: 996-998, 1992.
5. Landgraf, R. Antisense targeting in behavioural neuroendocrinology. J. Endocrinol. 151: 333-340, 1996.
6. Landgraf, R., R. Gerstberger, A. Montkowski, J. C. Probst, C. T. Wotjak, F. Holsboer, and M. Engelmann. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J. Neurosci. 15: 4250-4258, 1995.
7. 1 receptors in salt-sensitive hypertension in mRen-2 transgenic rats. Am. J. Physiol. 270 (Regulatory Integrative Comp. Physiol. 39): R1178-R1181, 1996.
8. Ludwig, M., M. Morris, and C. D. Sladek. Vasopressin antisense inhibits osmotically stimulated vasopressin but not oxytocin release. Soc. Neurosci. Abstr. 21: 875, 1995.
9. Mathiasen, J. R., D. Maciejewski-Lenoir, F. E. Bloom, and C. D. Sladek. Increased vasopressin secretion from hypothalamic cultures following administration of exogenous vasopressin mRNA. Exp. Neurol. 141: 165-172, 1996.
10. Meeker, R., G. LeGrand, J. Ramirez, T. Smith, and Y. H. Shih. Antisense vasopressin oligonucleotides: uptake, turnover, distribution, toxicity and behavioral effects. J. Neuroendocrinol. 7: 419-428, 1995.
11. Morris, M., P. Li, C. Barrett, and M. F. Callahan. Oxytocin antisense reduces salt intake in the baroreceptor denervated rat. Regul. Pept. 59: 261-266, 1995.
12. Morris, M., P. Li, M. F. Callahan, and A. B. Lucion. Central oxytocin mediated stress-induced tachycardia. J. Neuroendocrinol. 7: 455-459, 1995.
13. Morris, M., and A. B. Lucion. Antisense oligonucleotides in the study of neuroendocrine systems. J. Neuroendocrinol. 7: 493-500, 1995.
14. Neumann, I. Antisense oligonucleotides in neuroendocrinology: enthusiasm and frustration. Neurochem. Int. In press.
15. Neumann, I., P. Kremarik, and Q. J. Pittman. Acute, sequence-specific effects of oxytocin and vasopressin antisense oligonucleotides on neuronal responses. Neuroscience 69: 997-1003, 1995.
16. Neumann, I., D. W. F. Porter, R. Landgraf, and Q. J. Pittman. Rapid effect on suckling of an oxytocin antisense oligonucleotide administered into rat supraoptic nucleus. Am. J. Physiol. 267 (Regulatory Integrative Comp. Physiol. 36): R852-R858, 1994.
17. Phillips, M. I., and R. Gyurko. In vivo applications of antisense oligonucleotides for peptide research. Regul. Pept. 59: 131-142, 1995.